HROW

In the past six months, Harrow's stock price has significantly declined, falling 28% over the past year and 21.3% in the past month, reaching a new 52-week low of $27.00 on October 9, 2026. Key events include a wider-than-expected Q2 2026 loss of $0.46 per share, despite revenue slightly exceeding expectations, which resulted in a 446% increase in net loss compared to Q2 2025. On October 1, 2026, Harrow completed the acquisition of rights to TYRVAYA® outside Japan, an acquisition expected to contribute over $30 million in revenue in 2027. Despite recent stock performance, analysts maintain a 'Moderate Buy' consensus rating with an average price target of $66.17, suggesting significant upside, and some analysts reiterated 'Buy' ratings or initiated 'Outperform' coverage in September and October 2026. Additionally, Harrow insiders sold $450,000 in company stock in the past three months.